{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:38:24Z","timestamp":1792460304275,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014269","name":"Uniwersytet Medyczny w Bia\u0142ymstoku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","award":["B.SUB.25.103"],"award-info":[{"award-number":["B.SUB.25.103"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178290","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:41:57Z","timestamp":1761201717000},"page":"178290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients"],"prefix":"10.1016","volume":"1007","author":[{"given":"Katarzyna","family":"Wawrzak-Pienkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3169-1233","authenticated-orcid":false,"given":"Tomasz","family":"Pienkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Golonko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Warpechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Filip","family":"Plonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Mojsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178290_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000512277","article-title":"The role of calcium signaling in regulation of epithelial-mesenchymal transition","volume":"211","author":"Adiga","year":"2022","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.ejphar.2025.178290_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/JIR.S152835","article-title":"Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate\/nuclear factor- \u03baB pathway in vitro","volume":"11","author":"Al-Dwairi","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejphar.2025.178290_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ejphar.2025.178290_bib4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/cancers16081538","article-title":"From diabetes to oncology: glucagon-like peptide-1 (GLP-1) receptor agonist's dual role in prostate cancer","volume":"16","author":"Alhajahjeh","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178290_bib5","article-title":"Unlocking the multifaceted roles of GLP-1: physiological functions and therapeutic potential","volume":"14","author":"AL-Noshokaty","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.ejphar.2025.178290_bib6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2022.02.011","article-title":"Receptor-associated independent cAMP nanodomains mediate spatiotemporal specificity of GPCR signaling","volume":"185","author":"Anton","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178290_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178290_bib8","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.3390\/cancers14194651","article-title":"How far beyond diabetes can the benefits of glucagon-like peptide-1 receptor agonists go? A review of the evidence on their effects on hepatocellular carcinoma","volume":"14","author":"Arvanitakis","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178290_bib9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.178290_bib10","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1172\/JCI126309","article-title":"\u03b2 cell\u2013intrinsic \u03b2-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion","volume":"129","author":"Barella","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178290_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.178290_bib12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/en.2008-0625","article-title":"Sphingosine kinase as an oncogene: autocrine sphingosine 1-phoshate modulates ML-1 thyroid carcinoma cell migration by a mechanism dependent on protein kinase C-\u03b1 and ERK1\/2","volume":"150","author":"Bergelin","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178290_bib13","first-page":"2994","article-title":"S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1\/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration","volume":"151","author":"Bergelin","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178290_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.178290_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-009-1591-5","article-title":"Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?","volume":"53","author":"Butler","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.178290_bib16","doi-asserted-by":"crossref","first-page":"14302","DOI":"10.1074\/jbc.M115.655662","article-title":"Modulation of glucagon-like peptide-1 (GLP-1) potency by endocannabinoid-like lipids represents a novel mode of regulating GLP-1 receptor signaling","volume":"290","author":"Cheng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178290_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2025","article-title":"Hyperplasia from GLP-1 drugs is \u201cnot a surprise,\u201d say researchers","volume":"346","author":"Cohen","year":"2013","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2025.178290_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115234","article-title":"Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions","volume":"44","author":"Cote","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.178290_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2025.178290_bib20","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/oby.23772","article-title":"Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function","volume":"31","author":"De Barra","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.ejphar.2025.178290_bib21","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/biomedicines11061577","article-title":"Ca2+-mediated signaling pathways: a promising target for the successful generation of mature and functional stem cell-derived pancreatic beta cells in vitro","volume":"11","author":"Diane","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178290_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1085\/jgp.201210886","article-title":"Quantitative properties and receptor reserve of the IP3 and calcium branch of Gq-coupled receptor signaling","volume":"141","author":"Dickson","year":"2013","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejphar.2025.178290_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178290_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173102","article-title":"Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line","volume":"878","author":"Eftekhari","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2025.178290_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.178290_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106411","article-title":"Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics","volume":"184","author":"El Eid","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"6 5","key":"10.1016\/j.ejphar.2025.178290_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2025.178290_bib29","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"Elsayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.178290_bib30","article-title":"Longitudinal goal attainment with repeat injections of abobotulinumtoxinA in adults with lower limb spasticity: results from a prospective observational study","author":"Esquenazi","year":"2024","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ejphar.2025.178290_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091593","article-title":"Survival benefits of GLP-1 receptor agonists in patients with neuroendocrine neoplasms: a large-scale propensity-matched cohort study","volume":"17","author":"Fawzy","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178290_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ajpath.2014.09.009","article-title":"Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates","volume":"185","author":"Fiorentino","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2025.178290_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152869","article-title":"Pancreatic beta cell g-protein coupled receptors and second messenger interactions: a systems biology computational analysis","volume":"11","author":"Fridlyand","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178290_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178290_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1479164115605000","article-title":"Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis","volume":"13","author":"Gaspari","year":"2016","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejphar.2025.178290_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178290_bib37","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4 15","key":"10.1016\/j.ejphar.2025.178290_bib39","first-page":"1","article-title":"Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review","volume":"15","author":"Golonko","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178290_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2010.04.008","article-title":"PKC\u03b8 is necessary for efficient activation of NF\u03baB, NFAT, and AP-1 during positive selection of thymocytes","volume":"132","author":"Gruber","year":"2010","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejphar.2025.178290_bib41","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ejphar.2025.178290_bib42","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejphar.2025.178290_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/cd19-0079","article-title":"Oral semaglutide","volume":"38","author":"Hughes","year":"2020","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178290_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178290_bib46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcpt.13082","article-title":"Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis","volume":"123","author":"Ipsen","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178290_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178290_bib48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bph.15497","article-title":"The therapeutic potential of GLP-1 receptor biased agonism","volume":"179","author":"Jones","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178290_bib50","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016334","article-title":"Genetic and biased agonist-mediated reductions in \u03b2-arrestin recruitment prolong cAMP signaling at glucagon family receptors","volume":"296","author":"Jones","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178290_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.105692","article-title":"Protein kinase C signaling \u201cin\u201d and \u201cto\u201d the nucleus: master kinases in transcriptional regulation","volume":"300","author":"Kazanietz","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178290_bib52","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/db05-1145","article-title":"Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells","volume":"55","author":"Koehler","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib54","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178290_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178290_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","article-title":"The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells","volume":"132","author":"Ligumsky","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178290_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115167","article-title":"NFAT signaling dysregulation in cancer: emerging roles in cancer stem cells","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178290_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.178290_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-11077-w","article-title":"High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2025.178290_bib61","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: c-cell effects in mice are mediated via the glp-1 receptor and not associated with ret activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178290_bib62","article-title":"Thyroid hyperplasia and neoplasm adverse events associated with glucagon-like peptide-1 receptor agonists in the food and drug administration adverse event reporting system: retrospective analysis","volume":"5","author":"Makunts","year":"2024","journal-title":"JMIRx. med"},{"key":"10.1016\/j.ejphar.2025.178290_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.peptides.2013.01.014","article-title":"Glucagon-like peptides 1 and 2 in health and disease: a review","volume":"44","author":"Marathe","year":"2013","journal-title":"Peptides. (N.Y.)"},{"key":"10.1016\/j.ejphar.2025.178290_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.endien.2024.03.012","article-title":"Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis. Endocrinol","volume":"71","author":"Masson","year":"2024","journal-title":"Diabetes. Nutr. (English ed.)"},{"key":"10.1016\/j.ejphar.2025.178290_bib65","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetesinteractions with metformin","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.178290_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.178290_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.178290_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e16322","article-title":"The report of a single-arm, single-center, retrospective analysis investigating PD-L1 plus chemotherapy as adjuvant therapy in resected biliary tract cancer","volume":"43","author":"Mu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178290_bib70","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1\u2013based therapies increase cancer risk?","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2025.178290_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.178290_bib72","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","article-title":"Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth","volume":"63","author":"Nomiyama","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178290_bib73","article-title":"The clinical and molecular evaluation of the GIP\/GIPR axis in medullary thyroid cancer (MTC)","volume":"81","author":"Occhi","year":"2022","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.ejphar.2025.178290_bib74","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide \u2014 the FDA's review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1 15","key":"10.1016\/j.ejphar.2025.178290_bib75","first-page":"1","article-title":"Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk","volume":"15","author":"Piening","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178290_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108848","article-title":"Investigation into biased signaling, glycosylation, and drug vulnerability of acute myeloid leukemia","volume":"270","author":"Pienkowski","year":"2025","journal-title":"Pharmacol. Ther."},{"issue":"1 16","key":"10.1016\/j.ejphar.2025.178290_bib77","first-page":"1","article-title":"Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer","volume":"16","author":"Pienkowski","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178290_bib78","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/dom.14947","article-title":"Changes in the use of glucose-lowering drugs: a Danish nationwide study","volume":"25","author":"Potteg\u00e5rd","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.178290_bib79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.regpep.2010.04.005","article-title":"Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells","volume":"163","author":"Prabakaran","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2025.178290_bib80","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1074\/jbc.M109.067207","article-title":"GLP-1 mediates antiapoptotic effect by phosphorylating bad through a \u03b2-arrestin 1-mediated ERK1\/2 activation in pancreatic \u03b2-cells","volume":"285","author":"Quoyer","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178290_bib81","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00125-013-3130-7","article-title":"\u03b2-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice","volume":"57","author":"Ravier","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2025.178290_bib82","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/VHRM.S1707","article-title":"Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes","volume":"4","author":"Richter","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2025.178290_bib83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2025.178290_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of hepatocellular carcinoma with glucagon-like peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"Shabil","year":"2024","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ejphar.2025.178290_bib85","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00109-017-1508-6","article-title":"A role of PLC\/PKC-dependent pathway in GLP-1-stimulated insulin secretion","volume":"95","author":"Shigeto","year":"2017","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178290_bib86","article-title":"GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors","volume":"179","author":"Shilyansky","year":"2025","journal-title":"Surgery. (United States)"},{"key":"10.1016\/j.ejphar.2025.178290_bib87","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"issue":"4 17","key":"10.1016\/j.ejphar.2025.178290_bib88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: from simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178290_bib89","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1073\/pnas.0710402105","article-title":"\u03b2-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic \u03b2 cells","volume":"105","author":"Sonoda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.178290_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7346","article-title":"Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma","volume":"13","author":"Tan","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejphar.2025.178290_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178290_bib92","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/bph.16099","article-title":"Targeting G protein-coupled receptors for heart failure treatment","volume":"181","author":"Thai","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib93","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","article-title":"Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts","volume":"46","author":"Thompson","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.178290_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02100-y","article-title":"Beyond incretins: targeting neurokinin receptors for obesity treatment","volume":"10","author":"Thor","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178290_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceca.2017.07.008","article-title":"Regulation of insulin exocytosis by calcium-dependent protein kinase C in beta cells","volume":"67","author":"Trexler","year":"2017","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ejphar.2025.178290_bib96","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"},{"key":"10.1016\/j.ejphar.2025.178290_bib97","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bja.2024.01.001","article-title":"Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration","volume":"132","author":"van Zuylen","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejphar.2025.178290_bib98","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.3390\/ijms20123017","article-title":"Anti-cancer agents in proliferation and cell death: the calcium connection","volume":"20","author":"Varghese","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178290_bib99","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.178290_bib100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2025.178290_bib101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ebiom.2017.10.010","article-title":"Cyclic AMP-responsive element-binding protein (CREB) is critical in autoimmunity by promoting th17 but inhibiting treg cell differentiation","volume":"25","author":"Wang","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2025.178290_bib102","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib103","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/molecules28020751","article-title":"GLP-1R signaling and functional molecules in incretin therapy","volume":"28","author":"Wan","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178290_bib104","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1210\/jc.2011-2454","article-title":"Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"97","author":"Waser","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178290_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177309","article-title":"Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers","volume":"991","author":"Wawrzak-Pienkowska","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI. Insight"},{"issue":"10 19","key":"10.1016\/j.ejphar.2025.178290_bib107","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178290_bib108","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178290_bib109","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.2147\/OTT.S259853","article-title":"Inactivation of pancreatic stellate cells by exendin-4 inhibits the migration and invasion of pancreatic cancer cells","volume":"13","author":"Yan","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2025.178290_bib110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2006.10.001","article-title":"GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress","volume":"4","author":"Yusta","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.178290_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102235","article-title":"GLP-1R signaling does not modify the severity of experimental graft versus host disease","volume":"100","author":"Yusta","year":"2025","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2025.178290_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178290_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function","volume":"42","author":"Za\u00efmia","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.178290_bib114","article-title":"The novel dual GIP and GLP-1 receptor agonist tirzepatide attenuates colon cancer development by regulating glucose metabolism","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2025.178290_bib115","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.178290_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178290_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1387243","article-title":"Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1 8","key":"10.1016\/j.ejphar.2025.178290_bib118","first-page":"1","article-title":"\u03b2-arrestin-2 is an essential regulator of pancreatic \u03b2-cell function under physiological and pathophysiological conditions","volume":"8","author":"Zhu","year":"2017","journal-title":"Nat. Commun."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:37:27Z","timestamp":1779323847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925010441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":117,"alternative-id":["S0014299925010441"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178290","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178290"}}